En un ensayo clnico de fase 2, la semaglutida a dosis de 0,4mg diarios mostr una resolucin de NASH (sin empeoramiento de fibrosis) en un 59% de los pacientes, comparado con un 14% en el grupo placebo, en 320 pacientes con obesidad, NASH y fibrosis F2-F3 tras 72 semanas de tratamiento
Effect of henagliflozin on aging biomarkers in patients with type 2 diabetes: A multicenter, randomized, double-blind, placebo-controlled study
Proper technique inserted at 90 degrees quickly minimizes tissue trauma and associated pain sensations
Retatrutide Reconstitution Calculator Enter your vial size, BAC water volume, and target dose
Combination therapies, such as Miltefosine with Paromomycin or liposomal Amphotericin B, are also being investigated to improve effectiveness and reduce treatment duration ( Nanoparticle formulations of Amphotericin B, including topical options, are being trialed for safer, localized treatment of CL lesions ( 7 Emerging drug targets in Leishmania Recent advances in molecular and cellular biology have identified several promising drug targets that could pave the way for novel therapeutic interventions ( Leishmania parasites, suggesting its potential as a therapeutic target for visceral leishmaniasis (Wyllie et al., 2018)
Nakagawasai O, Tadano T, Hozumi S, Tan-No K, Niijima F, Kisara K, (2000) Brain Res Bull